Amphastar Pharmaceuticals, Inc. (AMPH)
21.51
-0.09
(-0.42%)
USD |
NASDAQ |
Aug 24, 16:00
21.51
0.00 (0.00%)
After-Hours: 20:00
Amphastar Pharmaceuticals Gross Profit Margin (Quarterly) : 48.73% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 48.73% |
| March 31, 2026 | 38.84% |
| December 31, 2025 | 44.70% |
| September 30, 2025 | 49.53% |
| June 30, 2025 | 47.30% |
| March 31, 2025 | 48.13% |
| December 31, 2024 | 44.70% |
| September 30, 2024 | 51.60% |
| June 30, 2024 | 50.47% |
| March 31, 2024 | 50.80% |
| December 31, 2023 | 52.53% |
| September 30, 2023 | 58.68% |
| June 30, 2023 | 50.13% |
| March 31, 2023 | 50.99% |
| December 31, 2022 | 50.83% |
| September 30, 2022 | 46.65% |
| June 30, 2022 | 49.25% |
| March 31, 2022 | 44.20% |
| December 31, 2021 | 44.30% |
| September 30, 2021 | 43.35% |
| June 30, 2021 | 43.69% |
| March 31, 2021 | 40.78% |
| December 31, 2020 | 35.60% |
| September 30, 2020 | 40.65% |
| June 30, 2020 | 35.80% |
| Date | Value |
|---|---|
| March 31, 2020 | 40.71% |
| December 31, 2019 | 37.46% |
| September 30, 2019 | 41.28% |
| June 30, 2019 | 38.26% |
| March 31, 2019 | 36.06% |
| December 31, 2018 | 37.25% |
| September 30, 2018 | 37.02% |
| June 30, 2018 | 34.39% |
| March 31, 2018 | 26.44% |
| December 31, 2017 | 30.93% |
| September 30, 2017 | 33.75% |
| June 30, 2017 | 39.33% |
| March 31, 2017 | 38.39% |
| December 31, 2016 | 29.58% |
| September 30, 2016 | 41.17% |
| June 30, 2016 | 44.88% |
| March 31, 2016 | 39.90% |
| December 31, 2015 | 41.96% |
| September 30, 2015 | 26.12% |
| June 30, 2015 | 22.89% |
| March 31, 2015 | 21.57% |
| December 31, 2014 | 21.40% |
| September 30, 2014 | 19.75% |
| June 30, 2014 | 30.60% |
| March 31, 2014 | 25.54% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Supernus Pharmaceuticals, Inc. | 72.88% |
| Liquidia Corp. | 93.10% |
| ANI Pharmaceuticals, Inc. | 54.97% |
| Corcept Therapeutics, Inc. | 98.41% |
| Veru, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 10.16% |
| Return on Assets | 4.70% |
| Return on Invested Capital | 5.45% |
| Profit Margin (Quarterly) | 16.50% |
| Operating Margin (Quarterly) | 21.60% |
| Return on Net Operating Assets | 6.16% |